Merck Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare
Rehan Verjee leaves his position as President of EMD Serono and Global Head of Innovative Medicine Franchises
Merck, a leading science and technology company, today announced that Rehan Verjee has made the decision to leave his position as President of EMD Serono and Global Head of Innovative Medicine Franchises, to pursue an opportunity outside of Merck that will soon be announced. He will be succeeded by Andrew Paterson, who is currently Senior Vice President and Head of both the Global Multiple Sclerosis (MS) Franchise and the MS business unit in the United States.
R&D facility at the Life Science site in St. Louis, USA
Merck KGaA
Paterson brings more than 30 years of leadership experience in the biopharmaceutical industry to his new appointment. He has an exceptional track record as a values- and results-driven leader of high-performing teams. His experience spans multiple specialty therapeutic areas including Neurology, Fertility, Endocrinology, and Cardiovascular diseases, in global launch, global portfolio strategy, and in-country leadership roles. Paterson is a recognized expert at launching new medicines and is one of the major architects behind the success of the company’s most recent multiple sclerosis medication and the return of its Global Neurology & Immunology Franchise to growth.
Paterson will be based in Rockland, Massachusetts, United States, and will serve as a member of the Healthcare Executive Committee.
Other news from the department people
